Hospira and partner receive notification

Hospira and a subsidiary of Warner Chilcott have announced they have received paragraph IV certification notices from Mutual and Mylan.

The notifications relate to the filing of an abbreviated new drug application (ANDA), for generic versions of Doryx 100 and 75 mg delayed-release tablets.

Under a license agreement with Hospira?s subsidiary Mayne, the drug is a tetracycline-class oral antibiotic protected by the 161 patent – number 6,958,161 – which expires in 2022.

Last month, Hospira announced Ken Meyers as senior vice president of organisational transformation and people development.

Under the role, Mr Meyers will lead the global human resources function, with a focus on advancing the company’s culture and organisation.

He succeeds Henry Weishaar, who is due to retire on December 31st.

Earlier in November, Hospira reported financial results for the third quarter of 2008.

The company’s net sales increased 10.4 per cent to $925.5 million (580.82 million pounds), compared to $838 million for the same period in 2007.

Diluted earnings per share increased by 28.6 per cent in the same period to $0.63, compared to $0.49 in the 2007’s third quarter.

Speaking at the time, chairman and chief executive officer Christopher Begley said the company was pleased by the “strong growth” achieved over the quarter.